You are here: Home: Audio Program Guide: CCU 1 | 2007: CCU 1 | 2007 Audio
 
  Go to interview with Robert A Wolff, MD
Go to interview with Jordan D Berlin, MD
Go to interview with Heinz-Josef Lenz, MD
  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Wolff, MD Robert A Wolff, MD
Associate Professor of Medicine
Deputy Chairman for Clinical Affairs
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Case discussion: A woman in her midfifties presenting with T3N1 rectal cancer
Track 3 Rationale for preoperative therapy in the treatment of rectal cancer
Track 4 Patient’s perception of the need for colorectal screening
Track 5 Phase II trial of preoperative capecitabine and bevacizumab combined with radiation therapy
Track 6 Capecitabine versus infusional 5-FU with preoperative radiation therapy
Track 7 Tolerability and response to neoadjuvant capecitabine/bevacizumab and radiation therapy
Track 8 Selection of postoperative adjuvant therapy in the treatment of rectal cancer
Track 9 Incorporating bevacizumab into adjuvant clinical trials
Track 10 Management of toxicities secondary to adjuvant capecitabine/oxaliplatin
Track 11 Incorporation of bevacizumab into neoadjuvant clinical trials for rectal cancer at MD Anderson
Track 12 Incorporation of oxaliplatin for the treatment of de novo metastases or as neoadjuvant therapy for rectal cancer
Track 13 Case discussion: A 78-year-old woman with T3N2M0 colon cancer and a history of stroke
Track 14 Comorbidities, performance status and age as predictors of tolerability to chemotherapy
Track 15 Case discussion: A 75-year-old man with a single focus of hepatic metastasis following resection of primary colon cancer
Track 16 Rationale for preoperative chemotherapy for resectable liver metastases
Track 17 Debulking metastatic tumors to allow for surgical resection
Track 18 Combining biologic agents in the treatment of colon cancer
Track 19 Allergic reactions and the choice of cetuximab versus panitumumab
     
  Jordan D Berlin, MD
Clinical Director GI Oncology
Associate Professor of Medicine
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Comparison of the EGFR inhibitors cetuximab and panitumumab in colon cancer
Track 3 Clinical trials with panitumumab
Track 4 Therapeutic algorithm for metastatic colon cancer
Track 5 Cetuximab-associated infusion reactions
Track 6 Incidence of infusion reactions for cetuximab versus panitumumab
Track 7 Combination therapy with an EGFR antibody and bevacizumab
Track 8 Chemotherapy plus double biologics for potentially curable hepatic metastases
Track 9 Predictors of response to EGFR inhibitors
Track 10 Novel agents and strategies to inhibit multiple pathways
Track 11 Clinical trials with multitargeted TKIs
Audio
Track 12 Potential mechanisms of action of bevacizumab
Audio
Track 13 Bevacizumab-associated side effects and use in the adjuvant setting
Audio
Track 14 Utilization of bevacizumab for elderly patients
Audio
Track 15 Implications of bevacizumab-associated hypertension
Audio
Track 16 Treatment of bevacizumab-associated hypertension
Audio
Track 17 Phase I trials of insulin growth factor receptor antagonists
Audio
Track 18 Potential impact of lifestyle modifications on risk of cancer recurrence
Audio
Track 19 Ongoing studies in the adjuvant and neoadjuvant settings
Audio
Track 20 Phase II study evaluating cetuximab with erlotinib
Audio
Track 21 Targeted therapy combining TKIs and antibody therapy
Audio
Track 22 Patients’ acceptance of serial biopsies in the clinical trial setting
Audio
Track 23 Rash secondary to combined TKI and antibody therapy
Audio
     
Lenz, MD Heinz-Josef Lenz, MD
Professor of Medicine and Preventative Medicine
Director, Colorectal Center
Director, GI Oncology Program
USC/Norris Comprehensive Cancer Center
Los Angeles, California

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Development of cetuximab and panitumumab
Track 3 Potential mechanisms of action of cetuximab and panitumumab
Track 4 Cetuximab-associated infusion reactions
Track 5 Relationship between infusion reactions and geographic variables
Track 6 Predictors of response to EGFR inhibitors
Track 7 Relationship between serum LDH and benefit from VEGF inhibitors
Track 8 Clinical management of metastatic colon cancer in the first-line setting
Track 9 Cetuximab-associated skin toxicity
Track 10 Clinical management of cetuximab-associated skin toxicity
Track 11 Considerations in evaluating bevacizumab and EGFR inhibitors in the adjuvant setting
Track 12 Assessment of EGFR
Track 13 Geographic variability in the side effects of fluoropyrimidines
Track 14 Relationship between folic acid and the side effects of fluoropyrimidines
Track 15 Mechanism of fluoropyrimidine toxicity
Track 16 Impact of diet and exercise on colorectal cancer